Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 3

Completed

Conditions: RET-fusion Non Small Cell Lung Cancer
Lung Neoplasm
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Disease
Carcinoma, Bronchogenic

Interventions: Drug: Pralsetinib
Drug: Carboplatin
Drug: Cisplatin
Drug: Pemetrexed
Drug: Pembrolizumab
Drug: Gemcitabine
Drug: Paclitaxel
Drug: Nab-Paclitaxel

First Posted Date: 2020-01-10

Last Posted Date: 2025-02-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 223

Registration Number: NCT04222972

Locations: 🇦🇷
Hospital Britanico, Buenos Aires, Argentina
🇫🇷
Hôpital Ambroise Paré - Boulogne-Billancourt, Boulogne Billancourt, France
🇫🇷
CHRU Lille Service de Pneumologie et Oncologie Thoracique, Lille, France

and more 64 locations

A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis

Phase 3

Active, not recruiting

Conditions: Lupus Nephritis

Interventions: Drug: Obinutuzumab
Drug: MMF
Drug: Prednisone
Drug: Placebo
Drug: Methylprednisolone
Drug: Acetaminophen
Drug: Diphenhydramine

First Posted Date: 2020-01-09

Last Posted Date: 2025-04-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 271

Registration Number: NCT04221477

Locations: 🇮🇹
A.O. Spedali Civili Di Brescia-P.O. Spedali Civili, Brescia, Lombardia, Italy
🇵🇪
Clínica San Juan Bautista CSJB, Lima, Peru
🇺🇸
NYU Langone Medical Center, New York, New York, United States

and more 70 locations

A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)

Phase 3

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Atezolizumab
Drug: Placebo
Drug: Bevacizumab
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Carboplatin

First Posted Date: 2019-12-11

Last Posted Date: 2024-07-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 305

Registration Number: NCT04194203

Locations: 🇨🇳
Guangxi Cancer Hospital of Guangxi Medical University, Nanning City, China
🇨🇳
First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, China
🇨🇳
Nan Tong Tumor Hospital, Nantong City, China

and more 20 locations

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Inavolisib
Drug: Placebo
Drug: Palbociclib
Drug: Fulvestrant

First Posted Date: 2019-12-09

Last Posted Date: 2025-04-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 325

Registration Number: NCT04191499

Locations: 🇨🇦
Hopital du Saint Sacrement, Quebec City, Quebec, Canada
🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳
The First Hospital of Jilin University, Changchun City, China

and more 135 locations

A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 3

Completed

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: Polatuzumab Vedotin
Drug: Rituximab
Drug: Gemcitabine
Drug: Oxaliplatin

First Posted Date: 2019-12-02

Last Posted Date: 2025-01-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 270

Registration Number: NCT04182204

Locations: 🇹🇷
Istanbul Uni Istanbul Medical Faculty, Istanbul, Turkey
🇺🇸
MSKCC at Basking Ridge, Basking Ridge, New Jersey, United States
🇮🇹
USL 4 di Prato - Nuovo Ospeale di Prato, Prato, Toscana, Italy

and more 64 locations

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Phase 3

Completed

Conditions: Triple-Negative Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Atezolizumab
Drug: Ipatasertib
Drug: Placebo for Atezolizumab
Drug: Placebo for Ipatasertib

First Posted Date: 2019-11-26

Last Posted Date: 2024-03-27

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 242

Registration Number: NCT04177108

Locations: 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
🇨🇦
McGill University; Glen Site; Oncology, Montreal, Quebec, Canada
🇨🇦
Royal Victoria Hospital, Barrie, Ontario, Canada

and more 178 locations

An Observational Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, in Participants With Haemophilia A Without Inhibitors Receiving Standard of Care Treatment

Completed

Conditions: Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor
Severe Hereditary Factor VIII Deficiency Disease Without Inhibitor
Haemophilia A

Interventions: Drug: Standard of Care for Haemophilia A

First Posted Date: 2019-11-15

Last Posted Date: 2024-07-12

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 103

Registration Number: NCT04165135

Locations: 🇮🇹
Ospedale Di Vicenza; Nefrologia, Ematologia, Vicenza, Veneto, Italy
🇮🇹
Az. Osp. Pugliese Ciaccio; S. C. Emofilia, Emostasi e Trombosi, Catanzaro, Calabria, Italy
🇮🇹
AOU Federico II; Medicina Clinica Chirurgia Centro Emocoaugulopatie e Emofilia, Napoli, Campania, Italy

and more 14 locations

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors

Phase 3

Active, not recruiting

Conditions: Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor
Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor
Hemophilia A

Interventions: Drug: Emicizumab

First Posted Date: 2019-11-12

Last Posted Date: 2025-05-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 73

Registration Number: NCT04158648

Locations: 🇪🇸
Hospital Universitario Virgen del Rocio, Sevilla, Spain
🇬🇧
Cardiff and Vale NHS Trust, Cardiff, United Kingdom
🇬🇧
Royal Free Hospital, London, United Kingdom

and more 19 locations

A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumors

Interventions: Drug: RO7296682

First Posted Date: 2019-11-12

Last Posted Date: 2024-03-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 76

Registration Number: NCT04158583

Locations: 🇧🇪
Cliniques Universitaires St-Luc, Bruxelles, Belgium
🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇨🇦
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada

and more 8 locations

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Ado-trastuzumab emtamsine
Drug: Atezolizumab
Drug: Capecitabine
Drug: Bevacizumab
Drug: Trastuzumab
Drug: Pertuzumab

First Posted Date: 2019-11-08

Last Posted Date: 2025-05-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 2907

Registration Number: NCT04158258

Locations: 🇧🇷
Instituto Brasileiro De Controle Do Câncer - IBCC, São Paulo, Brazil
🇦🇷
Sanatorio de la Mujer, Rosario, Argentina
🇧🇷
Hospital Jardim Amália, Volta Redonda, Rio De Janeiro, Brazil

and more 27 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy